Abstract 13212: A New Non-Vascular System to Treat Resistant Hypertension
INTRODUCTION: In the Western world, 30% to 40% of adults suffer from hypertension. Resistant hypertension (RH) prevalence has increased to over 25% of patients. To date, renal denervation to treat resistant hypertension has been utilized with radiofrequency (RF), ultrasound and drug eluding catheters placed arterially via the renal arteries. We evaluated a novel radiofrequency catheter (Verve Medical, Inc.) placed transurethrally into the renal pelvis in a pre-clinical model as a way to treat resistant hypertension (RH).
HYPOTHESIS: A non-vascular approach with no utilization of contrast may be an alternative method in treating RH.
METHODS: Sixteen female domestic swine weighing 60-65kg underwent renal pelvic denervation via ureteral access. Three animals were euthanized immediately after delivery of RF energy; five animals were survived for 7 days, 6 animals were survived for 14 days and 2 animals were survived for 30 days. Renal cortical norepinephrine levels were measured in all groups of animals. Histopathology of the treated zone was performed to confirm nerve damage. Renal cortical tissue was harvested for determination of tissue norepinephrine by HPLC. The kidneys were then profusion fixed and harvested for histopathologic analysis.
RESULTS: Mean reduction of norepinephrine levels was 60.4% compared to control. Histopathology confirmed nerve ablation in the treated zone. At the time of the presentation, Verve Medical’s initial human data will be presented.
CONCLUSION: In this small preclinical study, we introduce a new non-vascular system to treat resistant hypertension. We will present Verve Medical’s first human results. If the current clinical experience confirms efficacy and safety, this approach may be one way to treat patients who cannot be treated with the standard percutaneous arterial devices.
- © 2013 by American Heart Association, Inc.